Loading...

NichiiGakkan

DB:NG4
Snowflake Description

Second-rate dividend payer and slightly overvalued.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
NG4
DB
¥84B
Market Cap
  1. Home
  2. DE
  3. Healthcare
Company description

Nichiigakkan Co., Ltd. provides medical insurance administrative services for medical clinics in Japan and China. The last earnings update was 41 days ago. More info.


Add to Portfolio Compare Print
  • NichiiGakkan has significant price volatility in the past 3 months.
NG4 Share Price and Events
7 Day Returns
6.1%
DB:NG4
1.2%
DE Healthcare
0.7%
DE Market
1 Year Returns
17.7%
DB:NG4
-17.7%
DE Healthcare
-8.7%
DE Market
NG4 Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
NichiiGakkan (NG4) 6.1% 3.1% 24.8% 17.7% 59.7% 50.5%
DE Healthcare 1.2% 4% 20.1% -17.7% -15.1% 35.6%
DE Market 0.7% 2.2% 8.8% -8.7% 7.6% 9.7%
1 Year Return vs Industry and Market
  • NG4 outperformed the Healthcare industry which returned -17.7% over the past year.
  • NG4 outperformed the Market in Germany which returned -8.7% over the past year.
Price Volatility
NG4
Industry
5yr Volatility vs Market
Related Companies

Sorry, no analysis for NichiiGakkan's competitors could be found in our database.

Value

 Is NichiiGakkan undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of NichiiGakkan to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for NichiiGakkan.

DB:NG4 Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Average of 5 Analyst Estimates (S&P Global) See below
Discount Rate (Cost of Equity) See below 7%
Perpetual Growth Rate 10-Year DE Government Bond Rate 0.2%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for DB:NG4
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year DE Govt Bond Rate 0.2%
Equity Risk Premium S&P Global 6%
Healthcare Unlevered Beta Simply Wall St/ S&P Global 0.73
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 0.733 (1 + (1- 30.86%) (94.81%))
1.143
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
1.14
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 0.23% + (1.143 * 5.96%)
7.04%

Discounted Cash Flow Calculation for DB:NG4 using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for NichiiGakkan is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.

DB:NG4 DCF 1st Stage: Next 10 year cash flow forecast
Levered FCF (JPY, Millions) Source Present Value
Discounted (@ 7.04%)
2019 7,101.00 Analyst x1 6,634.03
2020 9,794.67 Analyst x3 8,548.80
2021 10,608.00 Analyst x2 8,649.81
2022 10,800.00 Analyst x1 8,227.25
2023 11,100.00 Analyst x1 7,899.72
2024 11,320.61 Est @ 1.99% 7,526.90
2025 11,485.85 Est @ 1.46% 7,134.56
2026 11,611.06 Est @ 1.09% 6,738.04
2027 11,707.61 Est @ 0.83% 6,347.28
2028 11,783.76 Est @ 0.65% 5,968.44
Present value of next 10 years cash flows ¥73,674.82
DB:NG4 DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2028 × (1 + g) ÷ (Discount Rate – g)
= ¥11,783.76 × (1 + 0.23%) ÷ (7.04% – 0.23%)
¥173,403.62
Present Value of Terminal Value = Terminal Value ÷ (1 + r)10
= ¥173,403.62 ÷ (1 + 7.04%)10
¥87,828.45
DB:NG4 Total Equity Value
Calculation Result
Total Equity Value = Present value of next 10 years cash flows + Terminal Value
= ¥73,674.82 + ¥87,828.45
¥161,503.27
Equity Value per Share
(JPY)
= Total value / Shares Outstanding
= ¥161,503.27 / 64.35
¥2509.88
DB:NG4 Discount to Share Price
Calculation Result
Non-primary Listing Adjustment Factor 1 share in DB:NG4 represents 0.0077x of TSE:9792
(This could be a different class, a depositary receipt, a different currency, or all of these things.)
0.0077x
Value per Share
(Listing Adjusted, EUR)
= Value per Share (JPY) x Listing Adjustment Factor
= ¥ 2,509.88 x 0.0077
€19.32
Value per share (EUR) From above. €19.32
Current discount Discount to share price of €10.02
= -1 x (€10.02 - €19.32) / €19.32
48.1%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

Current Discount
Amount off the current price NichiiGakkan is available for.
Intrinsic value
48%
Share price is €10.02 vs Future cash flow value of €19.32
Current Discount Checks
For NichiiGakkan to be considered undervalued it must be available for at least 20% below the current price. Less than 40% is even better.
  • NichiiGakkan's share price is below the future cash flow value, and at a moderate discount (> 20%).
  • NichiiGakkan's share price is below the future cash flow value, and at a substantial discount (> 40%).
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for NichiiGakkan's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are NichiiGakkan's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
DB:NG4 PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-12-31) in JPY ¥19.56
TSE:9792 Share Price ** TSE (2019-03-21) in JPY ¥1302
Germany Healthcare Industry PE Ratio Median Figure of 10 Publicly-Listed Healthcare Companies 34.11x
Germany Market PE Ratio Median Figure of 423 Publicly-Listed Companies 18.55x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of NichiiGakkan.

DB:NG4 PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= TSE:9792 Share Price ÷ EPS (both in JPY)

= 1302 ÷ 19.56

66.55x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • NichiiGakkan is overvalued based on earnings compared to the DE Healthcare industry average.
  • NichiiGakkan is overvalued based on earnings compared to the Germany market.
Price based on expected Growth
Does NichiiGakkan's expected growth come at a high price?
Raw Data
DB:NG4 PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section 66.55x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 5 Analysts
19%per year
Germany Healthcare Industry PEG Ratio Median Figure of 7 Publicly-Listed Healthcare Companies 1.1x
Germany Market PEG Ratio Median Figure of 275 Publicly-Listed Companies 1.44x

*Line of best fit is calculated by linear regression .

DB:NG4 PEG (Price to Earnings to Growth) Ratio Calculation
Calculation Outcome
PEG Ratio

= PE Ratio ÷ Net Income Annual Growth Rate

= 66.55x ÷ 19%

3.5x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • NichiiGakkan is poor value based on expected growth next year.
Price based on value of assets
What value do investors place on NichiiGakkan's assets?
Raw Data
DB:NG4 PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-12-31) in JPY ¥568.71
TSE:9792 Share Price * TSE (2019-03-21) in JPY ¥1302
Germany Healthcare Industry PB Ratio Median Figure of 12 Publicly-Listed Healthcare Companies 1.47x
Germany Market PB Ratio Median Figure of 571 Publicly-Listed Companies 1.79x
DB:NG4 PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= TSE:9792 Share Price ÷ Book Value per Share (both in JPY)

= 1302 ÷ 568.71

2.29x

* Primary Listing of NichiiGakkan.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • NichiiGakkan is overvalued based on assets compared to the DE Healthcare industry average.
X
Value checks
We assess NichiiGakkan's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Healthcare industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Healthcare industry average (and greater than 0)? (1 check)
  5. NichiiGakkan has a total score of 2/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is NichiiGakkan expected to perform in the next 1 to 3 years based on estimates from 5 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
19%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is NichiiGakkan expected to grow at an attractive rate?
  • NichiiGakkan's earnings growth is expected to exceed the low risk savings rate of 0.2%.
Growth vs Market Checks
  • NichiiGakkan's earnings growth is expected to exceed the Germany market average.
  • NichiiGakkan's revenue growth is positive but not above the Germany market average.
Annual Growth Rates Comparison
Raw Data
DB:NG4 Future Growth Rates Data Sources
Data Point Source Value (per year)
DB:NG4 Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 5 Analysts 19%
DB:NG4 Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 5 Analysts 4.1%
Germany Healthcare Industry Earnings Growth Rate Market Cap Weighted Average 2.8%
Germany Healthcare Industry Revenue Growth Rate Market Cap Weighted Average 5.4%
Germany Market Earnings Growth Rate Market Cap Weighted Average 11.4%
Germany Market Revenue Growth Rate Market Cap Weighted Average 5.7%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
DB:NG4 Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (2 months ago) See Below
Future Estimates Average of up to 5 Analyst Estimates (S&P Global) See Below
All numbers in JPY Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
DB:NG4 Future Estimates Data
Date (Data in JPY Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2023-03-31 339,200 13,805 4,860 1
2022-03-31 329,400 14,225 4,980 1
2021-03-31 312,010 14,377 5,313 4
2020-03-31 300,132 13,842 4,596 5
2019-03-31 288,310 11,401 2,913 2
DB:NG4 Past Financials Data
Date (Data in JPY Millions) Revenue Cash Flow Net Income *
2018-12-31 286,576 1,257
2018-09-30 284,937 10,698 187
2018-06-30 284,289 186
2018-03-31 283,767 15,802 854
2017-12-31 282,279 3,229
2017-09-30 280,334 16,452 3,561
2017-06-30 278,558 3,226
2017-03-31 276,659 9,379 1,403
2016-12-31 275,587 -13,273
2016-09-30 274,759 4,372 -14,939
2016-06-30 274,119 -16,143
2016-03-31 273,583 2,546 -15,995

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • NichiiGakkan's earnings are expected to grow by 19% yearly, however this is not considered high growth (20% yearly).
  • NichiiGakkan's revenue is expected to grow by 4.1% yearly, however this is not considered high growth (20% yearly).
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
DB:NG4 Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (2 months ago) See Below
Future Estimates Average of up to 5 Analyst Estimates (S&P Global) See Below

All data from NichiiGakkan Company Filings, last reported 2 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:NG4 Future Estimates Data
Date (Data in JPY Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2023-03-31 75.70 75.70 75.70 1.00
2022-03-31 77.60 77.60 77.60 1.00
2021-03-31 82.59 85.47 76.30 4.00
2020-03-31 71.50 90.40 60.30 5.00
2019-03-31 45.31 53.15 38.07 3.00
DB:NG4 Past Financials Data
Date (Data in JPY Millions) EPS *
2018-12-31 19.56
2018-09-30 2.91
2018-06-30 2.90
2018-03-31 13.30
2017-12-31 50.30
2017-09-30 55.47
2017-06-30 50.26
2017-03-31 21.86
2016-12-31 -206.77
2016-09-30 -232.72
2016-06-30 -251.48
2016-03-31 -248.82

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • NichiiGakkan is not expected to efficiently use shareholders’ funds in the future (Return on Equity less than 20%).
X
Future performance checks
We assess NichiiGakkan's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
NichiiGakkan has a total score of 2/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has NichiiGakkan performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare NichiiGakkan's growth in the last year to its industry (Healthcare).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • NichiiGakkan's year on year earnings growth rate was negative over the past 5 years, however the most recent earnings are above average.
  • NichiiGakkan's 1-year earnings growth is negative, it can't be compared to the 5-year average.
  • NichiiGakkan's 1-year earnings growth is negative, it can't be compared to the DE Healthcare industry average.
Earnings and Revenue History
NichiiGakkan's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from NichiiGakkan Company Filings, last reported 2 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:NG4 Past Revenue, Cash Flow and Net Income Data
Date (Data in JPY Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-12-31 286,576.00 1,257.00 43,566.00
2018-09-30 284,937.00 187.00 43,368.00
2018-06-30 284,289.00 186.00 43,425.00
2018-03-31 283,767.00 854.00 43,210.00
2017-12-31 282,279.00 3,229.00 43,040.00
2017-09-30 280,334.00 3,561.00 43,353.00
2017-06-30 278,558.00 3,226.00 43,661.00
2017-03-31 276,659.00 1,403.00 44,256.00
2016-12-31 275,587.00 -13,273.00 46,222.00
2016-09-30 274,759.00 -14,939.00 46,356.00
2016-06-30 274,119.00 -16,143.00 46,737.00
2016-03-31 273,583.00 -15,995.00 47,002.00
2015-12-31 272,851.00 -3,764.00 46,257.00
2015-09-30 272,428.00 -2,473.00 45,848.00
2015-06-30 272,026.00 -896.00 45,806.00
2015-03-31 271,868.00 416.00 45,391.00
2014-12-31 271,546.00 1,867.00 44,583.00
2014-09-30 271,413.00 1,764.00 44,969.00
2014-06-30 271,006.00 1,931.00 44,840.00
2014-03-31 271,447.00 2,831.00 45,341.00
2013-12-31 271,812.00 3,798.00 46,286.00
2013-09-30 271,108.00 4,611.00 46,110.00
2013-06-30 269,708.00 4,817.00 45,952.00
2013-03-31 267,191.00 4,383.00 45,002.00
2012-12-31 268,662.00 4,879.00 43,743.00
2012-09-30 266,130.00 5,121.00 42,221.00
2012-06-30 261,852.00 5,472.00 40,352.00
2012-03-31 257,340.00 5,897.00 38,604.00

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • NichiiGakkan has not efficiently used shareholders’ funds last year (Return on Equity less than 20%).
  • NichiiGakkan used its assets less efficiently than the DE Healthcare industry average last year based on Return on Assets.
  • NichiiGakkan has significantly improved its use of capital last year versus 3 years ago (Return on Capital Employed).
X
Past performance checks
We assess NichiiGakkan's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Healthcare industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
NichiiGakkan has a total score of 1/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is NichiiGakkan's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up NichiiGakkan's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • NichiiGakkan is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • NichiiGakkan's long term commitments exceed its cash and other short term assets.
Balance sheet
This treemap shows a more detailed breakdown of NichiiGakkan's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • High level of physical assets or inventory.
  • Debt is not covered by short term assets, assets are 0.8x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from NichiiGakkan Company Filings, last reported 2 months ago.

DB:NG4 Past Debt and Equity Data
Date (Data in JPY Millions) Total Equity Total Debt Cash & Short Term Investments
2018-12-31 37,076.00 79,434.00 19,479.00
2018-09-30 37,315.00 80,587.00 20,735.00
2018-06-30 36,802.00 82,282.00 18,030.00
2018-03-31 37,655.00 88,465.00 18,447.00
2017-12-31 38,082.00 81,915.00 17,151.00
2017-09-30 37,925.00 81,266.00 15,759.00
2017-06-30 37,725.00 91,394.00 14,816.00
2017-03-31 37,923.00 96,324.00 16,557.00
2016-12-31 35,954.00 85,807.00 14,169.00
2016-09-30 36,343.00 89,677.00 14,830.00
2016-06-30 36,605.00 88,577.00 15,160.00
2016-03-31 38,100.00 89,056.00 16,550.00
2015-12-31 51,931.00 74,603.00 16,470.00
2015-09-30 53,230.00 71,374.00 14,955.00
2015-06-30 53,608.00 70,564.00 15,019.00
2015-03-31 56,685.00 72,350.00 12,375.00
2014-12-31 60,807.00 52,443.00 11,724.00
2014-09-30 62,366.00 51,201.00 12,255.00
2014-06-30 61,900.00 53,713.00 11,096.00
2014-03-31 62,327.00 60,837.00 13,096.00
2013-12-31 62,123.00 45,796.00 11,621.00
2013-09-30 62,169.00 44,146.00 11,382.00
2013-06-30 61,548.00 41,697.00 10,176.00
2013-03-31 61,254.00 50,863.00 11,084.00
2012-12-31 59,601.00 45,579.00 8,869.00
2012-09-30 58,226.00 42,441.00 8,671.00
2012-06-30 57,375.00 44,205.00 8,282.00
2012-03-31 57,442.00 47,488.00 10,298.00
  • NichiiGakkan's level of debt (214.2%) compared to net worth is high (greater than 40%).
  • The level of debt compared to net worth has increased over the past 5 years (74% vs 214.2% today).
  • Debt is not well covered by operating cash flow (13.5%, less than 20% of total debt).
  • Interest payments on debt are not well covered by earnings (EBIT is 1.9x annual interest expense, ideally 3x coverage).
X
Financial health checks
We assess NichiiGakkan's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. NichiiGakkan has a total score of 1/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is NichiiGakkan's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
2.3%
Current annual income from NichiiGakkan dividends. Estimated to be 2.26% next year.
If you bought €2,000 of NichiiGakkan shares you are expected to receive €46 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • NichiiGakkan's pays a higher dividend yield than the bottom 25% of dividend payers in Germany (1.5%).
  • NichiiGakkan's dividend is below the markets top 25% of dividend payers in Germany (3.84%).
Upcoming dividend payment

Purchase NichiiGakkan on or before the 'Buy Limit' to receive their next dividend payment.

Dividends are usually paid every 3 or 6 months, you can time your share purchase to take advantage of upcoming dividend payments.
Dividend payment calendar
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
DB:NG4 Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 5 Analyst Estimates (S&P Global) See Below
Germany Healthcare Industry Average Dividend Yield Market Cap Weighted Average of 10 Stocks 1.6%
Germany Market Average Dividend Yield Market Cap Weighted Average of 331 Stocks 3.1%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.8%
Germany Bottom 25% Dividend Yield 25th Percentile 1.5%
Germany Top 25% Dividend Yield 75th Percentile 3.8%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

DB:NG4 Future Dividends Estimate Data
Date (Data in ¥) Dividend per Share (annual) Avg. No. Analysts
2023-03-31 30.00 1.00
2022-03-31 30.00 1.00
2021-03-31 30.00 4.00
2020-03-31 28.40 5.00
2019-03-31 30.00 4.00
DB:NG4 Past Annualized Dividends Data
Date (Data in ¥) Dividend per share (annual) Avg. Yield (%)
2019-02-08 30.000 2.408
2019-02-06 30.000 2.374
2018-11-09 30.000 2.787
2018-11-07 30.000 2.603
2018-06-27 30.000 2.934
2018-05-11 30.000 2.423
2018-02-09 22.000 1.865
2018-02-07 22.000 1.762
2017-11-10 22.000 1.570
2017-11-08 22.000 1.736
2017-06-09 22.000 1.919
2017-02-10 22.000 2.472
2017-02-08 22.000 2.585
2016-11-11 22.000 2.562
2016-11-09 22.000 2.553
2016-06-29 22.000 2.828
2016-05-13 22.000 3.167
2016-02-12 22.000 2.820
2016-02-10 22.000 2.854
2015-11-13 22.000 2.669
2015-11-10 22.000 2.561
2015-06-26 22.000 2.366
2015-05-14 22.000 2.126
2015-02-13 20.000 1.774
2015-02-09 20.000 1.727
2014-11-13 20.000 2.013
2014-11-07 20.000 2.342
2014-06-26 20.000 2.287
2014-05-14 20.000 2.221
2014-02-13 20.000 2.165
2014-02-07 20.000 2.332
2013-11-13 20.000 2.354
2013-11-07 20.000 2.288
2013-08-07 20.000 2.083
2013-06-27 18.000 2.054
2013-05-14 20.000 2.273
2013-02-12 18.000 2.037
2013-02-08 18.000 2.224
2012-11-12 18.000 2.607
2012-11-07 18.000 2.787
2012-08-07 18.000 2.414
2012-06-28 18.000 2.417
2012-05-15 18.000 2.351
2012-02-10 16.000 1.552
2012-02-09 16.000 1.680
2011-11-10 16.000 1.759
2011-11-07 16.000 1.841
2011-08-05 16.000 2.050
2011-06-29 16.000 2.243
2011-05-16 16.000 2.311
2011-02-09 14.000 2.108
2010-11-10 14.000 1.963
2010-08-10 14.000 1.914
2010-06-28 14.000 1.790
2010-05-17 14.000 1.640
2010-02-12 12.000 1.414
2010-02-09 12.000 1.453
2009-11-12 12.000 1.483
2009-11-10 12.000 1.476
2009-08-10 6.000 0.631
2009-05-19 6.000 0.655
2009-03-23 11.000 1.347

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Dividends per share have been stable in the past 10 years.
  • Dividends per share have increased over the past 10 years.
Current Payout to shareholders
What portion of NichiiGakkan's earnings are paid to the shareholders as a dividend.
  • Dividends paid are not well covered by earnings (0.8x coverage).
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess NichiiGakkan's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can NichiiGakkan afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. NichiiGakkan has a total score of 3/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of NichiiGakkan's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Akihiko Terada
COMPENSATION ¥309,969,000
AGE 82
CEO Bio

Mr. Akihiko Terada has been the President of Nichii Green Farm Co., Ltd. since May 2010. Mr. Terada has been the President of Tokyo Marunouchi Publication Co., Ltd. since May 1973. He serves as Chief Executive Officer of NichiiGakkan Co., Ltd. and served as its President since October 2014 until December 4, 2017. He served as President od Nihon Credit Lease Co., Ltd. since October 1998. He has been Representative Director and Chairman of Nihon Credit Lease Co., Ltd. since March 2002. He has been the Chairman and a Representative Director of NichiiGakkan Co., Ltd. since June 2005. He has been Representative Director, Australian Labradoodle Association Japan since April 2012. He has been Representative Director of Nichii Green Farm Co., Ltd. since May 2010. He served as Representative Director and President of Nihon Credit Lease Co., Ltd. since October 1998.

CEO Compensation
  • Insufficient data for Akihiko to compare compensation growth.
  • Akihiko's remuneration is lower than average for companies of similar size in Germany.
Management Team Tenure

Average tenure and age of the NichiiGakkan management team in years:

3.7
Average Tenure
53
Average Age
  • The tenure for the NichiiGakkan management team is about average.
Management Team

Akihiko Terada

TITLE
Chairman of the Board of Directors & CEO
COMPENSATION
¥310M
AGE
82

Nobusuke Mori

TITLE
President
AGE
54
TENURE
1.3 yrs

Daisuke Terada

TITLE
Executive VP
AGE
50

Takako Ide

TITLE
MD, GM of Business Division & Director
AGE
50
TENURE
3.9 yrs

Takayuki Masuda

TITLE
Senior MD
AGE
53
TENURE
3.4 yrs

Tsuyoshi Terada

TITLE
MD, GM of Business Strategy Division & Corporate Planning Division and Director
AGE
45

Etsuko Kuroki

TITLE
Dy GM-Core Business Div
AGE
52

Mitsuo Kaise

TITLE
GM of Business Management - Corporate Governance Division & Director
AGE
59
TENURE
3.9 yrs

Kayoko Kihara

TITLE
Managing Executive Officer
AGE
66

Yasuhiro Hiraoka

TITLE
Managing Executive Officer
Board of Directors Tenure

Average tenure and age of the NichiiGakkan board of directors in years:

9.3
Average Tenure
51
Average Age
  • The tenure for the NichiiGakkan board of directors is about average.
Board of Directors

Akihiko Terada

TITLE
Chairman of the Board of Directors & CEO
COMPENSATION
¥310M
AGE
82
TENURE
13.8 yrs

Nobusuke Mori

TITLE
President
AGE
54
TENURE
12.8 yrs

Daisuke Terada

TITLE
Executive VP
AGE
50
TENURE
20.8 yrs

Takako Ide

TITLE
MD, GM of Business Division & Director
AGE
50
TENURE
8.8 yrs

Tsuyoshi Terada

TITLE
MD, GM of Business Strategy Division & Corporate Planning Division and Director
AGE
45
TENURE
9.8 yrs

Etsuko Kuroki

TITLE
Dy GM-Core Business Div
AGE
52
TENURE
6.8 yrs

Mitsuo Kaise

TITLE
GM of Business Management - Corporate Governance Division & Director
AGE
59
TENURE
18.8 yrs

Keita Moriwaki

TITLE
Outside Director
AGE
45
TENURE
5.8 yrs

Yuji Sugimoto

TITLE
Outside Director
AGE
49
TENURE
3.8 yrs

Shuji Otomaru

TITLE
External Standing Corporate Auditor
AGE
67
TENURE
7.8 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
X
Management checks
We assess NichiiGakkan's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. NichiiGakkan has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Company Info

Description

Nichiigakkan Co., Ltd. provides medical insurance administrative services for medical clinics in Japan and China. The company offers medical support services, including medical care at hospitals, clinics, and pharmacies; support management and medical treatment through management consulting services and system sales, as well as personnel development in these fields through healthcare-related courses, such as medical office work. It also provides long-term care services from in-home care to long-term residential care in facilities, such as fee-based nursing homes; and training to personnel in long-term care fields through certification training programs and other courses related to long-term care. In addition, the company offers operates daycare centers, hospital daycare centers, company daycare centers, and other child care facilities; and corporate daycare centers to support the parenting efforts for employees and local residents, as well as child care courses, such as babysitting. Further, it provides a range of products and services related to household chores, child care, family nursing care, and elderly care; language education services; and postnatal care and housekeeping services. Additionally, the company operates dog salon based on the concept of pet health; and engages in the breeding of Australian labradoodles. Nichiigakkan Co., Ltd. was founded in 1968 and is based in Tokyo, Japan.

Details
Name: NichiiGakkan Co., Ltd.
NG4
Exchange: DB
Founded: 1968
¥666,277,048
64,346,978
Website: http://www.nichiigakkan.co.jp
Address: NichiiGakkan Co., Ltd.
2-9 Kanda-Surugadai,
Chiyoda-ku,
Tokyo,
101-8688,
Japan
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
TSE 9792 Common Stock The Tokyo Stock Exchange JP JPY 28. Jul 1995
DB NG4 Common Stock Deutsche Boerse AG DE EUR 28. Jul 1995
Number of employees
Current staff
Staff numbers
21,091
NichiiGakkan employees.
Industry
Health Care Services
Healthcare
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/03/21 22:03
End of day share price update: 2019/03/21 00:00
Last estimates confirmation: 2019/02/08
Last earnings filing: 2019/02/08
Last earnings reported: 2018/12/31
Last annual earnings reported: 2018/03/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.